Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Eliquis (apixaban)?

See the DrugPatentWatch profile for Eliquis

Eliquis® (apixaban)
A prescription oral anticoagulant (direct factor Xa inhibitor)

Category Details
Brand name Eliquis
Generic Apixaban
Drug class Direct oral anticoagulant (DOAC) – Factor Xa inhibitor
Approval FDA‑approved 2012 (US). Available in many other countries.

1. What Is Eliquis Used For?

Indication Typical Dose (Adults) Notes
Atrial fibrillation (AF) – stroke prevention 5 mg orally twice daily Reduces risk of ischemic stroke & systemic embolism
Deep venous thrombosis (DVT) / Pulmonary embolism (PE) 10 mg twice daily 7 days → 5 mg twice daily thereafter Treatment & prevention of recurrent events
Primary prevention of DVT/PE after hip/knee replacement surgery 5 mg twice daily for 10–14 days Reduces postoperative thrombotic risk

Why choose apixaban?
• Short half‑life (~12 h) – convenient dosing, quick onset/offset.
• No routine coagulation monitoring needed.
• Lower bleeding risk vs. warfarin in many trials (e.g., ARISTOTLE).
• Minimal food/drug interactions compared with some other DOACs.

2. How Does It Work?

  • Apixaban binds irreversibly to the active site of factor Xa, the key enzyme that converts prothrombin to thrombin.
  • By inhibiting factor Xa, it reduces thrombin generation → less fibrin clot formation.
  • No effect on vitamin K synthesis, so no dietary restrictions like warfarin.

3. Dosage & Administration

Situation Standard Dose How to Take
AF, DVT/PE treatment 5 mg twice daily With or without food. Avoid crushing or chewing.
DVT/PE treatment – 7 days 10 mg twice daily After 7 days, reduce to 5 mg BID.
Post‑surgery prophylaxis 5 mg twice daily for 10–14 days Start within 24 h after surgery (if adequate hemostasis).
Renal impairment Dose adjustment per eGFR eGFR ≥ 30 mL/min: 5 mg BID. eGFR < 30 mL/min: 2.5 mg BID.
Hepatic impairment Caution Not recommended if Child‑Pugh B or C.
Pregnancy Avoid No evidence for safety in humans.

Missed Dose

  • Take as soon as remembered, unless next dose is close. Then skip the missed dose. Do not double up.

Overdose

  • No specific antidote (see Reversal below). Manage bleeding with supportive measures and blood products.

4. Common Side Effects

Symptom Frequency Management
Bleeding (most important) ~2–4 % serious, higher in elderly/renal impairment Monitor for bruising, hematuria, melena, epistaxis; seek medical attention for prolonged bleeding.
Nausea, vomiting, dyspepsia 5–10 % Take with food, consider proton‑pump inhibitor.
Headache, dizziness <5 % Symptomatic treatment.
Rash, pruritus <2 % Topical steroids, antihistamines.

Remember: bleeding is the most serious adverse reaction; educate patients to report unusual bruising or blood in urine/stool.

5. Drug–Drug Interactions

Interacting Drug Effect on Apixaban Action
Strong CYP3A4 or P‑gp inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, lopinavir, amiodarone) ↑ Plasma levels Use caution; consider lower dose or avoid if possible.
Strong CYP3A4 or P‑gp inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s Wort) ↓ Plasma levels May reduce efficacy.
Other anticoagulants (warfarin, heparin, rivaroxaban, dabigatran) ↑ Bleeding risk Avoid unless necessary; monitor.
NSAIDs, aspirin, acetaminophen (high doses) ↑ Bleeding risk Use lowest effective dose, or avoid.
O‑phosphono‑methoxypropyl (O‑PMP) antibiotics (e.g., cefazolin) ↑ Bleeding risk Monitor.
Antiplatelet agents (clopidogrel, ticagrelor) ↑ Bleeding risk Consider combined risk/benefit.

Tip: Review all over‑the‑counter meds and supplements (e.g., ginkgo biloba, garlic) as they can potentiate bleeding.

6. Contraindications

  • Known hypersensitivity to apixaban or any component.
  • Severe hepatic impairment (Child‑Pugh B/C).
  • Active major bleeding.
  • Pregnancy (Category D – avoid).
  • Breastfeeding – evidence of drug in human milk; avoid if possible.

7. Precautions

Condition Recommendations
Renal impairment eGFR 30–50 mL/min: 5 mg BID. <30 mL/min: 2.5 mg BID. Monitor renal function every 3–6 months.
Hepatic impairment Use with caution; avoid if Child‑Pugh B/C.
Older adults Higher bleeding risk; consider dose adjustment if eGFR low.
History of GI ulcer/bleeding Evaluate risk vs. benefit; may need proton‑pump inhibitor.
Concurrent antiplatelet therapy Assess bleeding risk; consider dual therapy only when benefits outweigh risks.
Surgery Stop 24 h before low‑bleeding‑risk procedures; 48–72 h before high‑bleeding‑risk surgeries.
Dental procedures May be omitted if procedure is low bleeding risk; otherwise consider temporary discontinuation.

8. Reversal (Bleeding Management)

Antidote Availability Use
Andexanet alfa (Andexxa®) FDA‑approved (2021) Specific reversal of factor Xa inhibitors; indicated for life‑threatening bleeding or need for urgent surgery.
Prothrombin complex concentrates (PCCs) Commonly available Non‑specific reversal; useful when andexanet not available.
Vitamin K Not effective No effect on apixaban.
Activated charcoal If recent ingestion For overdose within 1 h of ingestion.
Supportive measures • Blood transfusion (packed RBCs, platelets)
• Fresh frozen plasma
• Surgical or interventional embolization		 For uncontrolled bleeding.

Key point: Andexanet alfa specifically binds apixaban and rivaroxaban; PCCs provide broad factor replacement. If a patient is on apixaban and needs emergent surgery or suffers severe bleeding, activate the reversal pathway immediately.

9. Special Populations

  • Pregnancy & Lactation: Animal studies show fetal harm. Avoid; if necessary, consider warfarin or low‑dose LMWH after consulting a maternal‑fetal medicine specialist.
  • Pediatric: Not approved; limited data.
  • Patients with mechanical heart valves: DOACs not recommended (RECORD‑AF). Use warfarin instead.

10. Patient Education Checklist

  1. Take exactly as prescribed – twice daily.
  2. Do not skip doses unless advised.
  3. Avoid alcohol (may increase bleeding risk).
  4. Report any unusual bruising, nosebleeds, blood in urine or stool promptly.
  5. Inform all healthcare providers (including dentists) before any invasive procedure.
  6. Check all medications for potential interactions (prescription, OTC, supplements).
  7. Keep an up‑to‑date medication list and share it with your care team.
  8. Know the signs of major bleeding: sudden swelling, severe headache, weakness, difficulty breathing, coughing up blood.
  9. Store medication at room temperature, away from moisture.


Other Questions About Eliquis :

When will eliquis paten expire? Is eliquis covered by insurance? Eliquis 价格? When does the eliquis patent protection end? Are there any discounts available for eliquis? When does the patent on Eliquis run out? What is the anticipated eliquis patent expiration date?

AI-Drug Label Prescribing Information Alignment Report

55
55%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Some claims align with the provided label excerpts (e.g., premature discontinuation warning and neuraxial/epidural hematoma counseling). However, many other claims are not verifiable from the supplied label excerpts, and several safety/clinical guidance statements are not supported by the provided text.

Category Scores

Indication
45
Partial
Dosage
50
Partial
Warnings
65
Good
DrugInteractions
30
Partial
Administration
60
Good

Accurate Statements

The boxed-style warnings excerpted (“Premature discontinuation…”, “Spinal/Epidural hematoma”) explicitly refer to ELIQUIS and describe effects of apixaban in the context of oral anticoagulant use and neuraxial procedures.
Warnings and Precautions (5.1) and (5.3) excerpts provided; Medication Guide and patient counseling excerpt provided in prompt.
Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.
Warnings and Precautions (5.1) provided in prompt.
When neuraxial anesthesia or spinal/epidural puncture is employed, patients treated with antithrombotic agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.
Warnings and Precautions (5.3) provided in prompt.
Patients should not discontinue ELIQUIS without talking to their physician first.
Patient Counseling excerpt in prompt: “Not to discontinue ELIQUIS without talking to their physician first.”
If any signs or symptoms of spinal or epidural hematomas occur, advise the patient to seek emergent medical attention.
Patient Counseling excerpt in prompt: “If any of these symptoms occur, advise the patient to seek emergent medical attention.”

Unsupported Statements

Apixaban helps prevent blood clots by reducing the activity of a key clotting factor involved in forming fibrin clots.
Mechanism/fibrin-clot formation explanation is not present in the provided label excerpts.
Apixaban is used to lower the risk of thromboembolic events.
Indication-specific statements are not supported by the provided excerpts.
Apixaban is used in common real-world settings such as atrial fibrillation.
No indication text (e.g., atrial fibrillation) is included in the provided excerpts beyond a brief mention in the 5.1 trial transition context; this does not substantiate a general “used in atrial fibrillation” claim.
Apixaban is used for treatment/prevention of venous clots.
No venous thromboembolism indication text is provided in the excerpts.
The specific indication depends on the approved dosing regimen in the product’s labeling.
No dosing regimen/indication mapping is included in the provided excerpts.
Apixaban directly inhibits Factor Xa.
The provided excerpts do not explicitly describe direct Factor Xa inhibition (the prompt only includes a general description: “apixaban (factor Xa inhibitor)” in the user-provided context, not in the label excerpts).
Blocking Factor Xa reduces thrombin generation.
Not present in provided label excerpts.
Reducing thrombin generation helps prevent clot formation.
Not present in provided label excerpts.
The right apixaban dose depends on the indication and patient factors such as kidney function and other clinical characteristics.
Kidney-function dosing adjustment guidance is not included in the provided excerpts.
Changes in kidney function can affect whether apixaban dosing needs adjustment.
Not present in provided excerpts.
Drug interactions can affect whether apixaban dosing needs adjustment.
No interaction/dose adjustment guidance is provided in the provided excerpts.
Bleeding history and planned procedures often affect whether apixaban dosing needs adjustment.
No dosing adjustment rules for bleeding history are provided in the excerpts.
The main risk with apixaban is bleeding.
The provided excerpts discuss thrombotic risk after discontinuation and spinal/epidural hematoma; they do not support a statement that “the main risk” is bleeding.
Patients should seek urgent care for signs of serious bleeding while taking apixaban.
Patient counseling excerpt provided is specifically about spinal/epidural hematoma signs, not general bleeding signs.
Serious bleeding signs while taking apixaban include heavy or uncontrolled bleeding, black/tarry stools, vomiting blood, unusual bruising.
These specific symptom examples are not included in the provided label excerpts.
Medication interactions are a major concern with anticoagulants.
No such interaction emphasis is provided in the excerpts.
Drugs that affect how apixaban levels change in the body can increase bleeding risk.
No pharmacokinetic interaction details are provided in the excerpts.
Drugs that affect how apixaban levels change in the body can reduce apixaban effectiveness.
No such interaction/efficacy effect is provided in the excerpts.
Certain antifungals/antibiotics and other agents that alter bleeding risk can change apixaban levels.
No drug class examples are provided in the excerpts.
Any new prescription or over-the-counter medicine should be reviewed with a clinician or pharmacist for apixaban interactions.
No general “review all new OTC meds” counseling is present in the provided excerpts.
Stopping or holding apixaban before surgery or dental work depends on the bleeding risk from the procedure and the patient’s clotting risk.
No pre-procedure stopping guidance for surgery/dental work is provided in the excerpts.
Clinicians use a tailored plan rather than a one-size-fits-all approach for stopping/holding apixaban before procedures.
Not present in the provided excerpts.
Patent and exclusivity timing can affect when generic versions or market alternatives become available for Eliquis (apixaban).
Not a prescribing-information claim and not supported by the provided label excerpts.
Alternatives to Eliquis (apixaban) include other anticoagulants used for similar indications.
No comparative alternatives text is provided in the excerpts.
Alternatives may include different factor Xa inhibitors depending on the patient’s situation.
No alternatives comparison is provided in the excerpts.
Switching anticoagulants generally requires clinician guidance because risks, dosing schedules, and interaction profiles differ by drug.
While some conversion guidance exists in the dosing section excerpt (2.5), the generalized claim about switching “generally” is not fully supported by provided excerpts.

Contradictions

Important Omissions

Specific boxed-warning content and/or spinal/epidural catheter timing details (e.g., “not removed earlier than 24 hours,” “next dose not earlier than 5 hours,” “delay 48 hours after traumatic puncture”) were not captured by the challenged claims.
Importance: Moderate
Monitoring specifics for neurologic impairment after neuraxial anesthesia (e.g., numbness/weakness, bowel/bladder dysfunction) were not included in the set of claims.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Some label-aligned counseling about not discontinuing without speaking to a physician and seeking emergent attention for spinal/epidural hematoma symptoms is present. However, many other claims about dosing, interactions, and specific serious bleeding symptom examples are unsupported by the provided label excerpts, increasing the chance of inaccurate patient-facing guidance.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Large portions of the claims are not supported by the provided label excerpts (indications, mechanism, dosing adjustments, interaction specifics, and general bleeding symptom lists).

Suggested Improvement
Limit claims to text supported by the supplied label excerpts (Warnings 5.1 and 5.3 and Patient Counseling). If evaluating additional label content (e.g., full indications, dosing, contraindications, drug interactions, and patient bleeding counseling), provide the corresponding label sections.

Drug Brand Mention Assessment

Branding Score
60
Visibility
64
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

prescription blood thinner (an anticoagulant)

Core Claims
  • Eliquis is a prescription blood thinner (an anticoagulant).
  • Its active ingredient is apixaban.
  • It helps prevent blood clots by reducing the activity of a key clotting factor involved in forming fibrin clots.
  • Apixaban is used to lower the risk of thromboembolic events.
  • The main risk with Eliquis (apixaban) is bleeding.
Differentiators
Pricing Perception: Not Mentioned